J Clin Trials 2018, 8:5
Nicole C. Hank, Jonathon Pereira, Brandon McCrave, Laura Christians, Chelsea Hoggan, Fabrice Dechoux.
Currently, over 50 million people worldwide are diagnosed with Alzheimer’s Disease (AD) and more than 16 million Americans suffer from Mild Cognitive Impairment (MCI). Despite unremitting scientific and clinical efforts, there has yet to be therapy that has abated disease progression. Currently there are no FDA approved medications for MCI and it has been over 15 years since a new therapy has been commercially available for AD. In the last two decades, clinical trials have focused on beta amyloid (Aβ), which has been known to play a key role in the pathogenesis of AD; however, drug therapies in AD research have had a 99.6% failure rate. With continuous and recent clinical trial failures, designing a clinical trial to examine different etiologies and studying underlying causes is warranted. In this study, 3 MCI and 2 AD patients who met eligibility criteria underwent cognitive and physiological testing, as well as cellular health assessments to test degrees of cognitive impairment, chronic inflammation, oxidative stress, metabolic issues, and cellular health. All study patients were then provided with a personalized Mito Food Plan, and four of the five subjects adjunctively underwent Cellular Repair Therapy. Results demonstrated significant improvements in cognitive testing scores, Quality of Life and reduction of chronic inflammation.